APRI (Aprinoia Therapeutics) ROE % Adjusted to Book Value: 0.00% (As of Dec. 2023)


What is Aprinoia Therapeutics ROE % Adjusted to Book Value?

Aprinoia Therapeutics APRI ROE % Adjusted to Book Value is 0.00% as of Dec. 2023.

Aprinoia Therapeutics's ROE % for the quarter that ended in Dec. 2023 was 0.00%. Aprinoia Therapeutics's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Aprinoia Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was N/A.

Aprinoia Therapeutics ROE % Adjusted to Book Value Related Terms

Aprinoia Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics ROE % Adjusted to Book Value Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
0.00 0.00 0.00

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value 0.00 0.00 0.00 0.00 0.00

APRI vs : ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Aprinoia Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aprinoia Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aprinoia Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Aprinoia Therapeutics's ROE % Adjusted to Book Value falls into.


Aprinoia Therapeutics ROE % Adjusted to Book Value Calculation

Aprinoia Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Aprinoia Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Aprinoia Therapeutics (APRI) has a ROE % Adjusted to Book Value of 0.00% as of Dec. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' ROE % Adjusted to Book Value too high?
Aprinoia Therapeutics' current ROE % Adjusted to Book Value is 0.00%.
How does Aprinoia Therapeutics' ROE % Adjusted to Book Value compare to ?
Aprinoia Therapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current ROE % Adjusted to Book Value is 0.00% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.